TRANSITION AGREEMENTTransition Agreement • November 7th, 2023 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Transition Agreement (this “Transition Agreement”), effective as of the date fully executed by the Parties (the “Transition Effective Date”), is by and among AbbVie Global Enterprises Ltd., a Bermuda corporation (“AbbVie”), and CytomX Therapeutics Inc., a Delaware corporation with offices at 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080 (“Licensor”). AbbVie and Licensor may each be referred to herein individually as a “Party” and collectively as the “Parties”.
